Senses Disorder TRIZ Cases

Modified isoquinolinone structures enhance binding affinity to resolve poor blood pressure control in hypertension treatments.

A lactic acid bacteria composition increases Th1-type cells and cytokine production.

A microinjector delivers triamcinolone into the suprachoroidal space of the eye.

Methyl-β-cyclodextrins encapsulate polyunsaturated fatty acids to prevent oxidation and maintain chemical stability in aqueous ophthalmic formulations.

Modified cyclosporin scaffolds reduce inflammation by inhibiting calcineurin, addressing inadequate symptom relief in dry eye treatment.

Viral vectors deliver Isl1 transcription factor to hair cells, attenuating age-related and noise-induced hearing loss.

Pyridine derivatives selectively inhibit Akt3 kinase activity to prevent glucose homeostasis defects.

Stable epoxymetabolite analogs resist enzymatic degradation, reducing treatment frequency for neovascularization disorders.

Variant ICOSL polypeptides modulate immune responses through targeted amino acid substitutions.

Peptide compositions inhibit toll-like receptor signaling to manage intense inflammatory responses in chronic otitis media.

Amino acid modifications in metastin derivatives enhance blood stability while maintaining cancer metastasis suppression activity.

Adeno-associated virus vectors deliver RP2 sequences to restore retinal photoreceptor function in mammalian models.

Imidazo[1,2-a]pyridine derivatives inhibit ALK-5 and ALK-4 kinases to block TGF-β signaling, reducing fibrosis in pulmonary hypertension.

DPP4 inhibitors block degradation of endogenous growth factors to promote alveolar type 2 cell proliferation and repair lung tissue damage.

Heterocyclic compounds enhance P2Y13 receptor activity to increase liver cell uptake of HDL-cholesterol.

Deuterium substitution strengthens carbon bonds in xanthine derivatives to slow metabolic degradation.

A potassium salt of a cyclooxygenase-2 inhibitor dissolves rapidly in neutral media.

Novel cannabinoid receptor modulators target CB1 and CB2 receptors to treat alcohol abuse disorders.

Ophthalmic nerve stimulation releases neuropeptides to improve ocular blood flow without systemic side effects.

CD79-specific antibodies inhibit Akt phosphorylation and CD86 expression to control aberrant B cell activity without depleting the immune population.

Merges carbonic anhydrase inhibition with adenosine A1 agonism to reduce intraocular pressure, addressing inadequate monotherapy efficacy.

Anhydrous polymorph A2 of Compound A resolves particle growth variability to ensure stable intraocular pressure treatment delivery.

Segmented monomeric units linked to activate FGFRs, resolving synthesis complexity while enhancing angiogenic specificity.

Pyrrolopyrimidine derivatives provide selective inhibition of mutated EGFR kinases through targeted molecular design.

A method primes mesenchymal stem cells with defined agents to produce exosomes with specific cargo profiles.

Administers EGFR inhibitors alongside Atoh1 gene therapy to resolve low conversion rates and immature morphology in hearing loss treatment.

Engineered allogeneic cells expressing B7 and 4-1BB agonists stimulate CD8+ T cell responses.

Novel amine compound inhibits semicarbazide-sensitive amine oxidase activity to treat inflammatory disorders and vascular diseases.

Novel peptide amide compound acts as a kappa opioid receptor agonist to deliver targeted analgesic activity.

Isolating small SSEA-4 positive mesenchymal stem cells from elderly donors using young donor extracellular matrix culture.

Modified 2-(azetidin-2-on-1-yl) alkanoic acids cross the blood-brain barrier to reach central nervous system receptors for treating depression and anxiety.

Macular pigments filter blue light to protect retinal tissues, reducing age-related macular degeneration risk in hyperopic patients.

Aldehyde trapping agents measure oxidative stress markers to adjust dosing frequency and manage ocular inflammation.

Alpha sKlotho fusion polypeptides enhance FGF receptor activation while reducing protease-induced cleavage to treat metabolic disorders.

A dual-vector adeno-associated virus system uses intein recombination to express full-length OTOF protein from split coding sequences.

Ring-closing metathesis of Formula I precursors forms lactones, enabling scalable synthesis of diverse prostaglandin analogs with high yields.

Modified AAV9 capsid and pR1.7 promoter enable efficient foveal cone transduction while avoiding macular detachment risks.

Linagliptin reduces sepsis mortality in diabetic patients by preserving organ function.

Modified rapamycin esters improve coating ductility to prevent cracking during expansion while maintaining drug stability.

Segmented erythropoietin peptides provide neuroprotection without triggering hematopoietic side effects.

Anti-secretogranin III antibodies treat retinal vascular leakage without harming normal vessels, enabling safer topical eye drop administration.

Polymorphic compounds scavenge toxic aldehydes to treat diseases where aldehyde toxicity drives pathogenesis.

Benzene compounds enhance retinal cell viability under oxidative stress and hypoxia, reducing choroidal neovascularization.

FSY and FTY peptides inhibit angiotensin-converting enzyme activity, addressing insufficient effectiveness and side effects of conventional ACE inhibitors.